Notizie su CSPC Pharmaceutical Group

Ultime notizie

Titoli nella lingua originale della fonte.

• CSPC to Present 8 ESMO 2026 Trials; Anbenitamab Breast Cancer Combo Gets NMPA Breakthrough Designation (si apre in una nuova scheda)

  Minichart · 5 ott 2026

• 
  Big Pharma Is Pouring Billions Into China’s Biotechs (si apre in una nuova scheda)

  Barrons.com · 14 set 2026

• 
  The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight (si apre in una nuova scheda)

  PR Newswire · 1 giu 2026

• 
  CSPC’s SYS6051 Trial Approval Adds New Angle To Valuation Story (si apre in una nuova scheda)

  Simply Wall St. · 22 apr 2026

• 
  2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation (si apre in una nuova scheda)

  PR Newswire · 22 apr 2026

• 
  Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint (si apre in una nuova scheda)

  PR Newswire · 1 apr 2026

• 
  How Regulatory Approval for CSPC Pharmaceutical’s First C5 siRNA Therapy (SEHK:1093) Has Changed Its Investment Story (si apre in una nuova scheda)

  Simply Wall St. · 7 nov 2025

• 
  Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates (si apre in una nuova scheda)

  GlobeNewswire · 4 nov 2025

• 
  How Dual U.S. and China Trial Approvals for SYH2070 Could Shape CSPC (SEHK:1093) Investors' Outlook (si apre in una nuova scheda)

  Simply Wall St. · 13 ott 2025